Dasatinib inhibits proinflammatory functions of mature human neutrophils

Krisztina Futosi, Tamás Németh, Robert Pick, T. Vántus, Barbara Walzog, A. Mócsai

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Dasatinib is a tyrosine kinase inhibitor used to treat imatinib-resistant chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. At present, little is known about how dasatinib influences nonmalignant cells. In the present study, we tested the effect of dasatinib on functional responses of normal mature human neutrophils. Dasatinib completely blocked integrin- and Fc-receptor-mediated neutrophil functions, with the lowest IC 50 values below 10nM under serum-free conditions. Dasatinib caused a partial inhibition of neutrophil responses triggered by G-protein-coupled receptors and had a moderate effect on neutrophil responses triggered by microbial compounds. Whereas dasatinib inhibited neutrophil chemotaxis under static conditions in 2 dimensions, it did not affect migration under flow conditions or in 3-dimensional environments. Dasatinib did not have any major effect on phagocytosis or killing of bacteria by neutrophils. Adhesion of human neutrophils in the presence of whole serum was significantly inhibited by 50-100nM dasatinib, which corresponds to the reported serum concentrations in dasatinib-treated patients. Finally, ex vivo adhesion of mouse peripheral blood neutrophils was strongly reduced after oral administration of 5 mg/kg of dasatinib. Those results suggest that dasatinib treatment may affect the proinflammatory functions of mature neutrophils and raise the possibility that dasatinib-related compounds may provide clinical benefit in neutrophil-mediated inflammatory diseases.

Original languageEnglish
Pages (from-to)4981-4991
Number of pages11
JournalBlood
Volume119
Issue number21
DOIs
Publication statusPublished - May 24 2012

Fingerprint

Neutrophils
Dasatinib
Adhesion
Serum
Philadelphia Chromosome
Fc Receptors
Chemotaxis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chromosomes
G-Protein-Coupled Receptors
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Phagocytosis
Integrins
Protein-Tyrosine Kinases
Oral Administration
Bacteria
Blood

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Dasatinib inhibits proinflammatory functions of mature human neutrophils. / Futosi, Krisztina; Németh, Tamás; Pick, Robert; Vántus, T.; Walzog, Barbara; Mócsai, A.

In: Blood, Vol. 119, No. 21, 24.05.2012, p. 4981-4991.

Research output: Contribution to journalArticle

Futosi, Krisztina ; Németh, Tamás ; Pick, Robert ; Vántus, T. ; Walzog, Barbara ; Mócsai, A. / Dasatinib inhibits proinflammatory functions of mature human neutrophils. In: Blood. 2012 ; Vol. 119, No. 21. pp. 4981-4991.
@article{6f03a34d54694e57b9ed5006936b0d4f,
title = "Dasatinib inhibits proinflammatory functions of mature human neutrophils",
abstract = "Dasatinib is a tyrosine kinase inhibitor used to treat imatinib-resistant chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. At present, little is known about how dasatinib influences nonmalignant cells. In the present study, we tested the effect of dasatinib on functional responses of normal mature human neutrophils. Dasatinib completely blocked integrin- and Fc-receptor-mediated neutrophil functions, with the lowest IC 50 values below 10nM under serum-free conditions. Dasatinib caused a partial inhibition of neutrophil responses triggered by G-protein-coupled receptors and had a moderate effect on neutrophil responses triggered by microbial compounds. Whereas dasatinib inhibited neutrophil chemotaxis under static conditions in 2 dimensions, it did not affect migration under flow conditions or in 3-dimensional environments. Dasatinib did not have any major effect on phagocytosis or killing of bacteria by neutrophils. Adhesion of human neutrophils in the presence of whole serum was significantly inhibited by 50-100nM dasatinib, which corresponds to the reported serum concentrations in dasatinib-treated patients. Finally, ex vivo adhesion of mouse peripheral blood neutrophils was strongly reduced after oral administration of 5 mg/kg of dasatinib. Those results suggest that dasatinib treatment may affect the proinflammatory functions of mature neutrophils and raise the possibility that dasatinib-related compounds may provide clinical benefit in neutrophil-mediated inflammatory diseases.",
author = "Krisztina Futosi and Tam{\'a}s N{\'e}meth and Robert Pick and T. V{\'a}ntus and Barbara Walzog and A. M{\'o}csai",
year = "2012",
month = "5",
day = "24",
doi = "10.1182/blood-2011-07-369041",
language = "English",
volume = "119",
pages = "4981--4991",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "21",

}

TY - JOUR

T1 - Dasatinib inhibits proinflammatory functions of mature human neutrophils

AU - Futosi, Krisztina

AU - Németh, Tamás

AU - Pick, Robert

AU - Vántus, T.

AU - Walzog, Barbara

AU - Mócsai, A.

PY - 2012/5/24

Y1 - 2012/5/24

N2 - Dasatinib is a tyrosine kinase inhibitor used to treat imatinib-resistant chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. At present, little is known about how dasatinib influences nonmalignant cells. In the present study, we tested the effect of dasatinib on functional responses of normal mature human neutrophils. Dasatinib completely blocked integrin- and Fc-receptor-mediated neutrophil functions, with the lowest IC 50 values below 10nM under serum-free conditions. Dasatinib caused a partial inhibition of neutrophil responses triggered by G-protein-coupled receptors and had a moderate effect on neutrophil responses triggered by microbial compounds. Whereas dasatinib inhibited neutrophil chemotaxis under static conditions in 2 dimensions, it did not affect migration under flow conditions or in 3-dimensional environments. Dasatinib did not have any major effect on phagocytosis or killing of bacteria by neutrophils. Adhesion of human neutrophils in the presence of whole serum was significantly inhibited by 50-100nM dasatinib, which corresponds to the reported serum concentrations in dasatinib-treated patients. Finally, ex vivo adhesion of mouse peripheral blood neutrophils was strongly reduced after oral administration of 5 mg/kg of dasatinib. Those results suggest that dasatinib treatment may affect the proinflammatory functions of mature neutrophils and raise the possibility that dasatinib-related compounds may provide clinical benefit in neutrophil-mediated inflammatory diseases.

AB - Dasatinib is a tyrosine kinase inhibitor used to treat imatinib-resistant chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. At present, little is known about how dasatinib influences nonmalignant cells. In the present study, we tested the effect of dasatinib on functional responses of normal mature human neutrophils. Dasatinib completely blocked integrin- and Fc-receptor-mediated neutrophil functions, with the lowest IC 50 values below 10nM under serum-free conditions. Dasatinib caused a partial inhibition of neutrophil responses triggered by G-protein-coupled receptors and had a moderate effect on neutrophil responses triggered by microbial compounds. Whereas dasatinib inhibited neutrophil chemotaxis under static conditions in 2 dimensions, it did not affect migration under flow conditions or in 3-dimensional environments. Dasatinib did not have any major effect on phagocytosis or killing of bacteria by neutrophils. Adhesion of human neutrophils in the presence of whole serum was significantly inhibited by 50-100nM dasatinib, which corresponds to the reported serum concentrations in dasatinib-treated patients. Finally, ex vivo adhesion of mouse peripheral blood neutrophils was strongly reduced after oral administration of 5 mg/kg of dasatinib. Those results suggest that dasatinib treatment may affect the proinflammatory functions of mature neutrophils and raise the possibility that dasatinib-related compounds may provide clinical benefit in neutrophil-mediated inflammatory diseases.

UR - http://www.scopus.com/inward/record.url?scp=84861519200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861519200&partnerID=8YFLogxK

U2 - 10.1182/blood-2011-07-369041

DO - 10.1182/blood-2011-07-369041

M3 - Article

C2 - 22411867

AN - SCOPUS:84861519200

VL - 119

SP - 4981

EP - 4991

JO - Blood

JF - Blood

SN - 0006-4971

IS - 21

ER -